We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 | 1.44% | 76.97 | 76.50 | 76.98 | 76.80 | 75.96 | 76.34 | 4,911,684 | 00:59:15 |
From May 2021 to May 2024
By Cecilia Butini
AstraZeneca PLC said Friday that real-world data coming from Canada suggest that its Covid-19 vaccine is effective against hospitalization or death from disease caused by virus variants after just one dose.
According to study results from the Canadian Immunization Research Network, Public Health Agency of Canada and the Canadian Institutes of Health Research, one dose of AstraZeneca's vaccine is 82% effective at preventing hospitalization or death caused by the coronavirus's Beta and Gamma variants. The same dose is also seen as effective at preventing hospitalizations and deaths from the virus's Delta variant, with 87% effectiveness against hospitalizations and 90% effectiveness in preventing death, the company said.
Study results were published as a pre-print, meaning they haven't yet been peer-reviewed.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 23, 2021 04:42 ET (08:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
